Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Sponsor: Revolution Medicines, Inc.

Sponsor score: 0

ClinicalTrials ID:NCT07621718

This Phase 3, double-blind study assesses zoldonrasib plus chemotherapy versus placebo plus chemotherapy in untreated metastatic KRAS G12D-mutated pancreatic adenocarcinoma. Participants must be 18+, with ECOG 0-1, confirmed diagnosis, and adequate organ function. Interventions include oral zoldonrasib/placebo and IV chemotherapy options like mFFX or GnP.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

Description

This is a Phase 3, global, randomized, double-blind study designed to evaluate whether treatment with zoldonrasib in combination with Investigator choice of chemotherapy will improve progression-free survival or overall survival compared to placebo in combination with Investigator choice of chemotherapy when given to patients with previously untreated, 1L metastatic KRAS G12D-mutated pancreatic adenocarcinoma. Choice of chemotherapy (mFFX or GnP) will be at the discretion of the Investigator.

Patients will be randomized to one of two arms: zoldonrasib + Investigator choice of chemotherapy (Arm A) or placebo + Investigator choice of chemotherapy (Arm B).

Eligibility Criteria

Inclusion Criteria

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed pancreatic adenocarcinoma.
  • Diagnosis of metastatic disease ≤ 6 weeks prior to screening.
  • Documented KRAS G12D mutation status.
  • Measurable disease per RECIST v1.1.
  • Adequate organ function (bone marrow, liver, kidney, coagulation).
  • Able to take oral medications.

Exclusion Criteria

  • Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting.
  • Prior systemic RAS-targeted therapy any time prior to randomization.
  • Presence of other known driver mutations with approved targeted therapies
  • Active or known history of untreated central nervous system metastatic disease.
  • Any conditions that may affect the ability to take or absorb study drug.
  • Major surgery within 28 days prior to randomization.
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures.

Locations

FACILITYZIPCITYSTATE
Piedmont Healthcare30318AtlantaGeorgia

Get This Program In Your Inbox

You can sign up and apply your patients for this program.